Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven W Lane

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Blood|August 18, 2023
Genome-wide transcription factor-binding maps reveal cell-specific changes in the regulatory architecture of human HSPCsShruthi Subramanian, Julie A I Thoms, Yizhou Huang, et al.
Nature Immunology|October 13, 2020
Transcriptome dynamics of CD4<sup>+</sup> T cells during malaria maps gradual transit from effector to memoryMegan S F Soon, Hyun Jae Lee, Jessica A Engel, et al.
Nature|November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasmsAshok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Cell Reports|February 27, 2020
Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral LeishmaniasisRajiv Kumar, Patrick T Bunn, Siddharth Sankar Singh, et al.
Cancer Discovery|March 21, 2022
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AMLJessica M Salmon, Izabela Todorovski, Kym L Stanley, et al.
Blood|April 7, 2021
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemiasRachel Thijssen, Sarah T Diepstraten, Donia Moujalled, et al.
Blood|October 25, 2021
PLCG1 is required for AML1-ETO leukemia stem cell self-renewalTina M Schnoeder, Adrian Schwarzer, Ashok Kumar Jayavelu, et al.
Science Translational Medicine|February 23, 2018
Oncogenic JAK2<sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasmsAlessandro Prestipino, Alica J Emhardt, Konrad Aumann, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Blood|August 18, 2023
Genome-wide transcription factor-binding maps reveal cell-specific changes in the regulatory architecture of human HSPCsShruthi Subramanian, Julie A I Thoms, Yizhou Huang, et al.
Nature Immunology|October 13, 2020
Transcriptome dynamics of CD4<sup>+</sup> T cells during malaria maps gradual transit from effector to memoryMegan S F Soon, Hyun Jae Lee, Jessica A Engel, et al.
Nature|November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasmsAshok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Cell Reports|February 27, 2020
Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral LeishmaniasisRajiv Kumar, Patrick T Bunn, Siddharth Sankar Singh, et al.
Cancer Discovery|March 21, 2022
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AMLJessica M Salmon, Izabela Todorovski, Kym L Stanley, et al.
Blood|April 7, 2021
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemiasRachel Thijssen, Sarah T Diepstraten, Donia Moujalled, et al.
Blood|October 25, 2021
PLCG1 is required for AML1-ETO leukemia stem cell self-renewalTina M Schnoeder, Adrian Schwarzer, Ashok Kumar Jayavelu, et al.
Science Translational Medicine|February 23, 2018
Oncogenic JAK2<sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasmsAlessandro Prestipino, Alica J Emhardt, Konrad Aumann, et al.
Pageof 11